NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

ATL-DC is the experimental and L (murcidencel non proprietary name) is the commercial scale product that has passed equivalence studies along the way with manufacturing changes. You conveniently keep forgetting that you said anyone can make a DC vaccine and that is true including the one approved in India and Provenge. The question is who has the commercial scale needed and sufficient to optimum activation equivalence which includes DC chemokine and cytokine production characteristics. This and various forms of IP protection in place are what makes a product commercially viable and likely to be profitable. Differences in the process of making DCs is not what’s most important. What is important is that they turn out with the desired characteristics to adequately treat the targeted disease state and that is what makes ATL-DC and L the same and is something Dr. Linda Liau and others would know for sure based on actual data but not you. Best wishes.